[A25-25] Atezolizumab (NSCLC, first line) – Addendum to Project A24-97

Last updated 20.03.2025

Project no.:
A25-25

Commission:
Commission awarded on 11.02.2025 by the Federal Joint Committee (G-BA).

Report type:
Addendum

Status:
Commission completed

Department/Division:
Drug Assessment

Topic:
Cancer

Indication:

First-line treatment of advanced non-small cell lung cancer in adult patients for whom platinum-based chemotherapy is not an option and whose tumours have no EGFR mutations or ALK translocations

Result of dossier assessment:

after addendum now:

Patients with PD-L1 expression ≥ 50% on tumour cells: added benefit not proven
Patients with PD-L1 expression < 50% on tumour cells: indication of minor added benefit

Note:

If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.

DOI:

https://doi.org/10.60584/A25-25_en